Anixa Biosciences Lira-cel CAR-T Therapy Shows Positive Survival Data in Ovarian Cancer Phase 1 Trial

Key Takeaways

• Lira-cel CAR-T therapy demonstrates positive survival outcomes in ongoing Phase 1 ovarian cancer trial
• Moffitt Cancer Center will present clinical data at the International Society for Cell & Gene Therapy 2026 Annual Meeting
• Results represent potential breakthrough for ovarian cancer patients with limited treatment options

---

SAN JOSE, Calif. – April 22, 2026 – Anixa Biosciences (NASDAQ: ANIX) announced that its investigational CAR-T cell therapy Lira-cel continues to show encouraging survival data in patients with ovarian cancer, with results to be presented at the prestigious International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting.

Cheryl Cox, MHA, Operations Director of the Cell Therapies and Gene Expression Engineering Facility at Moffitt Cancer Center, will present the clinical findings from the ongoing Phase 1 trial. The presentation highlights the potential of Lira-cel as a novel treatment approach for ovarian cancer, a disease that affects approximately 22,000 women annually in the United States.

Clinical Significance and Market Impact

The positive survival data represents a significant milestone for Anixa Biosciences’ oncology pipeline. Ovarian cancer remains one of the most challenging gynecologic malignancies, with a five-year survival rate of approximately 49% across all stages. Current treatment options are limited, particularly for patients with recurrent or treatment-resistant disease.

CAR-T (Chimeric Antigen receptor T-cell) therapy represents a cutting-edge approach in cancer treatment, genetically modifying a patient’s own immune cells to better recognize and attack cancer cells. While CAR-T therapies have shown remarkable success in blood cancers, their application in solid tumors like ovarian cancer has proven more challenging.

Partnership and Development

The collaboration with Moffitt Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center, strengthens the clinical development program. Moffitt’s expertise in cell therapy manufacturing and clinical research provides crucial support for advancing Lira-cel through clinical trials.

The ISCT Annual Meeting serves as a premier forum for presenting breakthrough research in cell and gene therapy. The selection of Anixa’s data for presentation indicates the scientific community’s recognition of Lira-cel’s potential therapeutic value.

Looking Forward

As the Phase 1 trial continues, investors and patients will closely monitor additional safety and efficacy data. The company has not yet disclosed timelines for potential Phase 2 studies or regulatory submissions, but the positive survival trends suggest continued development momentum for this innovative ovarian cancer treatment approach.

---

Frequently Asked Questions

What is Lira-cel and how does it work?

Lira-cel is an investigational CAR-T cell therapy that genetically modifies a patient’s immune cells to better recognize and attack ovarian cancer cells, representing a personalized immunotherapy approach.

When will Lira-cel be available to patients?

Lira-cel is currently in Phase 1 clinical trials. It will need to complete additional clinical phases and receive FDA approval before becoming commercially available, which typically takes several years.

How does this compare to current ovarian cancer treatments?

Current ovarian cancer treatments primarily include surgery, chemotherapy, and targeted therapies. CAR-T therapy like Lira-cel represents a novel immunotherapy approach that could potentially offer benefits for patients who don’t respond to conventional treatments.